Semaglutide / Tirzepatide
A compounded injection combining semaglutide and tirzepatide, prescribed after a provider evaluation as part of a medically supervised weight program. It is not FDA approved.
Compounded drugs are not FDA approved. FDA does not review compounded drugs for safety, effectiveness, or quality before marketing.
See it before your first visit
Photographs of the medication as dispensed.
What it is
Semaglutide / Tirzepatide is a compounded injection that combines semaglutide, a GLP-1 receptor agonist, with tirzepatide, a GIP and GLP-1 receptor agonist. It is prescribed by a licensed provider as part of a medically supervised weight program.
It is a compounded medication. It is not FDA approved, and the FDA has not evaluated it for safety, effectiveness, or quality. There is limited clinical evidence on using semaglutide and tirzepatide together.
How it works
Semaglutide mimics a hormone called GLP-1, and tirzepatide mimics GLP-1 and a second hormone called GIP. Both affect appetite and digestion. Because both ingredients act on the GLP-1 pathway, your provider will explain the dose, how it is adjusted over time, and how to inject it.
What to expect
Your provider will decide how to start and adjust your dose and will review your progress and side effects at follow-ups. Nausea, vomiting, constipation, and diarrhea are common, especially after a dose change. Results vary and no outcome is guaranteed.
Who it is for
This injection is prescribed by a licensed provider after an evaluation. It is not appropriate for everyone. Tell your provider if you or a family member has had medullary thyroid carcinoma or MEN 2, or if you have pancreatitis, gallbladder disease, kidney disease, diabetes, or are pregnant or breastfeeding. Do not use this product together with any other semaglutide or tirzepatide medication.
Side effects
Common side effects include nausea, vomiting, diarrhea, constipation, stomach pain, and tiredness. Serious effects can include pancreatitis, gallbladder problems, kidney injury from dehydration, and allergic reactions. Contact your provider if you have severe stomach pain, persistent vomiting, a lump or swelling in your neck, trouble swallowing, or signs of an allergic reaction.
Read this before you start
Compounded drugs are not FDA approved. FDA does not review compounded drugs for safety, effectiveness, or quality before marketing.
Medication availability, formulation, packaging and pharmacy fulfillment vary based on the patient's prescription and location.
Compounded medication. This medication is compounded by a pharmacy for an individual patient. It is not FDA approved, and the FDA has not evaluated it for safety, effectiveness, or quality.
Limited evidence. There is limited clinical evidence on the safety and effectiveness of combining semaglutide and tirzepatide. Combining two medications that act on the same pathway may increase the risk and severity of side effects. Report any new or severe symptoms to your provider.
Boxed warning, thyroid C-cell tumors. Semaglutide and tirzepatide medications carry a boxed warning for risk of thyroid C-cell tumors. Do not use if you or a family member has had medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Other risks. Pancreatitis, gallbladder disease, kidney problems from dehydration, low blood sugar when used with insulin or sulfonylureas, and diabetic retinopathy changes are possible. Tell your provider before any procedure that uses anesthesia or sedation.
Birth control. Tirzepatide may reduce the effectiveness of oral birth control pills. Ask your provider about backup contraception.
Pregnancy. Do not use if you are pregnant or planning to become pregnant.
Injection safety. Use a new sterile needle each time, rotate sites, and dispose of sharps safely. Do not share needles or vials.
This page is for general information and is not medical advice.
Common questions
Is Semaglutide / Tirzepatide FDA approved?
No. It is a compounded medication. The FDA has not evaluated it for safety, effectiveness, or quality.
What is in it?
Semaglutide and tirzepatide.
Has the combination been studied?
There is limited clinical evidence on using the two together. Your provider will discuss what is and is not known.
How is it given?
As a subcutaneous injection, following your provider's directions.
Can I use it with other GLP-1 medications?
No. Do not use it with any other semaglutide or tirzepatide product.
%20(1)%20(1)%20(1).png)